PKB

Dong suggested that mutated lung adenocarcinomas with increased mutation burden showed remarkable medical benefit to PD-1 inhibitors [21]

Dong suggested that mutated lung adenocarcinomas with increased mutation burden showed remarkable medical benefit to PD-1 inhibitors [21]. with reduced progression-free (= 0.024) and overall… Read More »Dong suggested that mutated lung adenocarcinomas with increased mutation burden showed remarkable medical benefit to PD-1 inhibitors [21]